明胶改性壳聚糖纤维表征及其体内降解特点

目的：采用明胶处理壳聚糖纤维,考察其表征及在大鼠肌袋内的生物相容性.方法：实验于2006-09/2007-01在解放军第八十九医院全军创伤骨科研究所实验室完成.①实验分组：分别以磷酸盐缓冲液、50,100 g/L明胶处理壳聚糖纤维.②实验评估：测定壳聚糖纤维膨胀率、拉伸强度;扫描电镜、红外光谱观察壳聚糖纤维的形态及结构;分离大鼠脊柱两侧椎旁肌肉形成3个肌袋,分别植入经γ射线灭菌的3种纤维20 mg.术后1周,1,3个月将纤维连同包膜完整取出,计算体内降解率.另取标本连同周围肌肉行苏木精-伊红染色. 结果：①壳聚糖纤维的膨胀率及拉伸强度：磷酸盐缓冲液组纤维膨胀率最高,拉伸强度最小;100 g/L明胶组膨胀率最低,拉伸强度最大.100 g/L明胶组拉伸强度与磷酸盐缓冲液组和50 g/L明胶组间差异有显著性意义（P＜0.05）,3组壳聚糖纤维膨胀率差异无显著性意义.②壳聚糖纤维的形态和结构：扫描电镜下磷酸盐缓冲液组纤维束交织,结构略显松散,50、100 g/L明胶改性后纤维结构更为致密.红外光谱分析显示明胶和壳聚糖间有相互作用.③体内降解率：磷酸盐缓冲液组体内平均降解率65%,50,100 g/L明胶组平均降解率分别为78%和81%,3组间差异无显著性意义.④壳聚糖纤维植入肌袋后的组织相容性：改性后壳聚糖纤维植入后与大鼠周围肌肉连接紧密,表面包膜薄,细胞主要为淋巴细胞,植入12周后3组纤维大部分吸收. 结论：明胶改性可进一步提高壳聚糖纤维的强度和生物相容性.     

外源性一氧化氮对创伤愈合过程中一氧化氮合酶表达及瘢痕形成的影响

目的:应用组织化学、免疫组织化学及计算机辅助图像分析方法,观察外源性一氧化氮在创伤愈合过程不同时间,对一氧化氮合酶表达和胶原形成的影响,探讨其在促进创伤愈合和抑制病理性瘢痕形成中的机制。方法:实验于2004-09/2006-03在河北省人民医院整形烧伤外科及河北省人民医院临床医学研究中心完成。以硝普钠为一氧化氮供体,将60只大鼠随机分为对照组及硝普钠0.5,1,2,4mmol/L组,每组12只,通过建立大鼠创伤模型,并分别在创面局部应用50g/L葡萄糖溶液、0.5,1,2,4mmol/L硝普钠,观察及测量创伤后3,7,10,14d的肉芽组织生长情况、一氧化氮合酶的表达情况和肉芽组织中羟脯氨酸含量。结果:60只大鼠全部进入结果分析。①形态学观察:对照组于创伤后14d可完全愈合;硝普钠0.5mmoL/L组及1mmoL/L组肉芽组织生长良好,且愈合时间较对照组提前三四天;硝普钠2mmoL/L组及4mmoL/L组愈合情况不良,完全愈合时间延迟,皮肤张力较低,炎症反应明显。②一氧化氮合酶蛋白表达:大鼠皮肤创伤后角质形成细胞、汗腺、毛囊和骨骼肌细胞以及创伤后肉芽组织的炎症细胞、成纤维细胞、血管内皮细胞均不同程度的表达一氧化氮合酶蛋白。对照组在第3天和第14天分别呈现一氧化氮合酶阳性颗粒表达高峰,而硝普钠各组仅在第7～10天出现表达一氧化氮合酶阳性高峰,呈先增加后减少的趋势。③羟脯氨酸含量:对照组从创伤后第3,7,10,14天羟脯氨酸含量进行性增加[依次为(1.637±0.127),(2.250±0.169),(2.420±0.201),(2.908±0.241)mg/g];硝普钠0.5mmol/L组在创伤后第3,7天羟脯氨酸含量低于对照组[(1.435±0.147),(1.766±0.211)mg/g,P<0.05或P<0.01],而在第10天和第14天羟脯氨酸含量均高于对照组[(3.128±0.240),(3.437±0.239)mg/g,P<0.01];硝普钠1mmol/L组和2mmol/L组在第10天和第14天的羟脯氨酸含量明显高于对照组[(1mmol/L组:(3.244±0.245)(3.582±0.282)mg/g,P<0.01;硝普钠2mmol/L组:(3.666±0.263),(4.301±0.268)mg/g,P<0.01);硝普钠4mmol/L组仅在创伤后第3天表现比对照组多[(1.912±0.139)mg/g,P<0.01),其余均与对照组水平相近。结论:局部应用外源性一氧化氮具有显著的促修复作用,主要体现在伤后第7～10天,小剂量的一氧化氮促进创面愈合的作用远远大于大剂量一氧化氮。     

Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors

Three distinct complementary DNAs for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been cloned and designated VIP-1 receptor (VIP-1R), VIP-2 receptor (VIP-2R), and PACAP receptor (PACAP-R). In the present study, we have characterized the binding sites on primary mouse calvarial osteoblasts for VIP and related peptides. By analyzing the cAMP response, the rank order of response observed was PACAP 38 > PACAP 27 > helodermin > VIP > helospectin > glucagon > PHI > secretin. The VIP-2R/PACAP-R antagonist, PACAP 6-38, inhibited both VIP- and PACAP-stimulated cAMP formation. Binding studies using an atomic force microscopy (AFM) technique showed high affinity binding for VIP and PACAP 38, but not for secretin. Radioligand binding studies using (125)I-VIP and (125)I-PACAP 38 demonstrated a more specific and higher affinity binding for PACAP 38 than for VIP. Secretin failed to inhibit both (125)I-VIP and (125)I-PACAP 38 binding. RT-PCR demonstrated that undifferentiated mouse calvarial osteoblasts express messenger RNA for VIP-2R, but not for VIP-1R or PACAP-R. When the osteoblasts were cultured for 20 days to induce bone noduli formation, VIP-1R, in addition to VIP-2R, were expressed when the nodules started to mineralize at 12 days. Taken together, these data demonstrate that mouse calvarial osteoblasts express functional VIP-2R with higher affinity binding for PACAP than for VIP and that the VIP-1R expression is induced during osteoblastic differentiation.     

Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis

Methotrexate (MTX) is one of the most widely prescribed drugs in the treatment of rheumatoid arthritis (RA). The mechanism by which MTX exerts its anti-rheumatic effect has not yet been defined. The aim of the present study was to investigate the effect of MTX treatment (7.5- 15 mg/week) on synovial tissue in RA. For this purpose, synovial biopsies were taken from 11 RA patients before and 16 weeks after initiation of MTX therapy. Immunohistochemistry was performed using monoclonal antibodies (MAb) specific for CD3, CD4, CD8, CD22, CD25, CD38, CD68, MAb67, Ki67, interferon gamma (IFN-gamma), interleukin (IL)- 1alpha, IL-1beta, tumour necrosis factor alpha (TNF-alpha), E-selectin, ICAM-1 and VCAM-1. All parameters for disease activity improved during the period of treatment. Immunohistochemical analysis revealed a statistically significant decrease in scores for CD3, CD8, CD38, CD68, Ki67, IL-1beta, TNF-alpha and the adhesion molecules E-selectin and VCAM-1. The observed decrease in synovial scores for inflammatory cells, monokines and adhesion molecules suggests that the anti- inflammatory effect of MTX is, in part, dependent on a reduction in monokine-inducible vascular adhesion molecules and subsequent reduction of cell traffic into joints.      

The American Digestive Health Foundation: Advancing digestive health through support of research and education in the cause, prevention, treatment, and cure of digestive diseases

This article has no abstract. To view the article, select the "View Print Version (PDF)" link above.     

Effects of hematopoietin-1 and interleukin 1 activities on early hematopoietic cells of the bone marrow

Hematopoietin-1 (H-1) was purified from the human cell line 5637 and two amino acid sequences were observed in the preparation. One sequence was identical to that of interleukin 1 alpha (IL 1 alpha) and the other to that of IL 1 beta. The action of recombinant IL 1 alpha and other hematopoietic growth factors was studied using (a) a high proliferative potential colony-forming cell assay that uses primitive hematopoietic precursors from bone marrow, and (b) a spleen colony-forming unit assay. The results indicate that the IL 1 alpha target cell population is different than the target cell populations of IL 3, granulocyte- macrophage colony-stimulating factor; that IL 1 alpha in combination with mononuclear phagocyte colony-stimulating factor provides a proliferative stimulus; and that IL 1 alpha has at least a survival- enhancing and possibly proliferation-inducing effect on primitive hematopoietic stem cells.     

Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenases (COX) and are widely used for post-trauma musculoskeletal analgesia. In animal models, NSAIDs have been reported to delay fracture healing and cause non-union, possibly due to the drug-induced inhibition of osteoblast recruitment and differentiation. To further investigate the cellular effects of these drugs in the context of bone healing, we examined the effects of COX-1 inhibitor indomethacin and COX-2 inhibitors, parecoxib and NS398 on osteoclast and osteoblast differentiation and activity in vitro. We discovered that all tested COX-inhibitors significantly inhibited osteoclast differentiation, by 93%, 94% and 74% of control for 100 microM indomethacin, 100 microM parecoxib and 3 microM NS398, respectively. Furthermore, inhibition of COX-2 reduced also the resorption activity of mature osteoclasts. All tested COX-inhibitors also significantly inhibited osteoblast differentiation from human mesenchymal stem cells. Simultaneously, the number of adipocytes was significantly increased. The adipocyte covered areas in the cultures with 1 microM indomethacin, 1 microM parecoxib and 3 microM NS398 were 9%, 29% and 24%, respectively, as compared with 6% in the control group. This data suggests that COX-2 inhibition disturbs bone remodelling by inhibiting osteoclast differentiation and diverting stem cell differentiation towards adipocyte lineage instead of osteoblast lineage. In conclusion, our results further suggest cautious use of COX-2 inhibitors after osseous trauma.